lanoteplase - SUN-9216 - SUN9216 - SUN 9216
All results are NS for efficacy
Mortalité à long terme 0.97 [0.88; 1.07]
Hémorragies majeures précoces 0.83 [0.53; 1.31]
Mortalité précoce 1.02 [0.90; 1.16]
AVC précoce 1.22 [0.94; 1.59]
lanoteplase 120 KU. kg(-1) as a single intravenous bolus (n=10038)
vs.
up to 100 mg accelerated alteplase given over 90 min (n=5022)
double blind
Parallel groups
Sample size: 10038/5022
Primary endpoint: Mortality 30-day
FU duration: 30 days